AbbVie stock rallies to $251.52 with strong bullish momentum despite overbought signals

Traders Union
All News
Companies
AbbVie up 3.45% to $251.52 today

Highlights

AbbVie surged 16.1% from last week to $251.52, reaching a 52-week high with strong bullish momentum.
Momentum indicators are firmly bullish but signal short-term overbought conditions, showing buying dominance and possible near-term exhaustion.
The projected range for next week is $251.14 to $255.20, with a breakout above $255.20 likely to trigger new record highs.

Bullish structure reinforced as price holds above key moving averages

AbbVie ($251.52) is trading well above its SMA-20 ($225.87), SMA-50 ($214.75), and SMA-200 ($221.25), confirming a strong bullish structure across short-, medium-, and long-term timeframes. The Ichimoku Kijun at $230.39 sits below the current price and acts as immediate support; near-term support is clustered at the Ichimoku Kijun and SMA-20 ($225.87), with key support at SMA-50 ($214.75), while near-term resistance is set at today’s high ($251.78) and the 52-week high, with key resistance at projected psychological levels above these technical markers.

Upward breakout and overbought signals as momentum and volatility intensify

Momentum signals are robust on D1, with a bullish MACD and RSI of 75.85 indicating strong upward pressure, while ADX at 16.86 suggests a trend that is present but not extremely strong. Multiple oscillators (Stoch RSI at 100, CCI at 252.55, BBP at 20.34) flag overbought conditions, showing buyers’ dominance intraday. The Awesome Oscillator also signals in favor of the bullish trend. In today’s session, AbbVie gained 3.45%, rising sharply from the previous close. AbbVie has jumped $34.89 (16.11%) from last week’s close at $216.63. The price is now at the very top of the weekly range, and weekly volatility stands at 13.45%. This marks a strong upward breakout rather than mere consolidation, with momentum and price reinforcing each other but also pointing to a near-term overextension.

Further upside favored as price tests highs and downside risk fades

For the coming week, the expected range is $251.14 to $255.20, aligning closely with the new highs and staying comfortably within 20% of the current price. The probability of a further price increase is very high (more than 80%), supported by a full set of "Buy" signals across W1 moving averages and RSI W1, while further downside remains very unlikely. Baseline scenario: AbbVie consolidates within a narrow corridor near record highs. Bullish scenario: a breakout above $255.20 could trigger further gains and new all-time highs. Bearish scenario: a fall below $251.14 could induce mild profit-taking toward support at $230.39–$225.87. This latest surge puts AbbVie at its 52-week high, far above its yearly low of $181.75, indicating powerful upward momentum yet with signs of short-term exhaustion.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that AbbVie's strong momentum was supported by strategic acquisitions and regulatory advancements, with expectations for consolidation after significant gains. In light of recent developments, investors should now focus on emerging signals that could determine whether the current trend evolves into a sustained breakout or faces increased volatility.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.